NFKB1 and diffuse large B-cell lymphoma: Our in vitro experiments found that these anti-NF-κB agents can effectively inhibit p65 protein expression and DNA binding activity, leading to cell cycle arrest, decreased cell proliferation, and apoptosis induction in both GCB and ABC types of p65-overexpressing DLBCL cell lines.